U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination
    • Showing Current items.

    Il34 interleukin 34 [ Mus musculus (house mouse) ]

    Gene ID: 76527, updated on 21-Apr-2024

    GeneRIFs: Gene References Into Functions

    GeneRIFPubMed TitleDate
    Interleukin-34-NF-kappaB signaling aggravates myocardial ischemic/reperfusion injury by facilitating macrophage recruitment and polarization.

    Interleukin-34-NF-κB signaling aggravates myocardial ischemic/reperfusion injury by facilitating macrophage recruitment and polarization.
    Zhuang L, Zong X, Yang Q, Fan Q, Tao R., Free PMC Article

    10/4/2023
    IL-34 exacerbates pathogenic features of Alzheimer's disease and calvaria osteolysis in triple transgenic (3x-Tg) female mice.

    IL-34 exacerbates pathogenic features of Alzheimer's disease and calvaria osteolysis in triple transgenic (3x-Tg) female mice.
    Ho A, Ngala B, Yamada C, Garcia C, Duarte C, Akkaoui J, Ciolac D, Nusbaum A, Kochen W, Efremova D, Groppa S, Nathanson L, Bissel S, Oblak A, Kacena MA, Movila A., Free PMC Article

    09/22/2023
    TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice.

    TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice.
    Xie X, Zhang W, Xiao M, Wei T, Qiu Y, Qiu J, Wang H, Qiu Z, Zhang S, Pan Y, Mao L, Li Y, Guo B, Yang W, Hu Y, Hu S, Gong Y, Yang J, Xiao G, Zhang Y, Bai X., Free PMC Article

    07/6/2023
    Inactivating IL34 promotes regenerating muscle stem cell expansion and attenuates Duchenne muscular dystrophy in mouse models.

    Inactivating IL34 promotes regenerating muscle stem cell expansion and attenuates Duchenne muscular dystrophy in mouse models.
    Su Y, Cao Y, Liu C, Xu Q, Li N, Lan M, Li L, Wang K, Zhang Z, Meng Q., Free PMC Article

    05/30/2023
    BMP-2 Genome-Edited Human MSCs Protect against Cartilage Degeneration via Suppression of IL-34 in Collagen-Induced Arthritis.

    BMP-2 Genome-Edited Human MSCs Protect against Cartilage Degeneration via Suppression of IL-34 in Collagen-Induced Arthritis.
    Chae DS, Han S, Lee MK, Kim SW., Free PMC Article

    05/22/2023
    Il-34 regulates MAPKs, PI3K/Akt, JAK and NF-kappaB pathways and induces the expression of inflammatory factors in RA-FLS.

    Il-34 regulates MAPKs, PI3K/Akt, JAK and NF-κB pathways and induces the expression of inflammatory factors in RA-FLS.
    Yang H, Luo Y, Lai X.

    10/15/2022
    IL-34 deficiency impairs FOXP3(+) Treg function in a model of autoimmune colitis and decreases immune tolerance homeostasis.

    IL-34 deficiency impairs FOXP3(+) Treg function in a model of autoimmune colitis and decreases immune tolerance homeostasis.
    Freuchet A, Salama A, Bézie S, Tesson L, Rémy S, Humeau R, Règue H, Sérazin C, Flippe L, Peterson P, Vimond N, Usal C, Ménoret S, Heslan JM, Duteille F, Blanchard F, Giral M, Colonna M, Anegon I, Guillonneau C., Free PMC Article

    09/3/2022
    IL-34 and protein-tyrosine phosphatase receptor type-zeta-dependent mechanisms limit arthritis in mice.

    IL-34 and protein-tyrosine phosphatase receptor type-zeta-dependent mechanisms limit arthritis in mice.
    González-Sánchez HM, Baek JH, Weinmann-Menke J, Ajay AK, Charles JF, Noda M, Franklin RA, Rodríguez-Morales P, Kelley VR.

    07/30/2022
    Bone morphogenetic protein 2 controls steroid-induced osteonecrosis of the femoral head via directly inhibiting interleukin-34 expression.

    Bone morphogenetic protein 2 controls steroid-induced osteonecrosis of the femoral head via directly inhibiting interleukin-34 expression.
    Wang M, Min HS, Shan H, Lin Y, Xia W, Yin F, Jiang C, Yu X.

    03/19/2022
    Interleukin-34 accelerates intrauterine adhesions progress related to CX3CR1(+) monocytes/macrophages.

    Interleukin-34 accelerates intrauterine adhesions progress related to CX3CR1(+) monocytes/macrophages.
    Wang J, Li D, Pan Y, Li J, Jiang Q, Liu D, Hou Y.

    12/25/2021
    Fate decision of satellite cell differentiation and self-renewal by miR-31-IL34 axis.

    Fate decision of satellite cell differentiation and self-renewal by miR-31-IL34 axis.
    Su Y, Yu Y, Liu C, Zhang Y, Liu C, Ge M, Li L, Lan M, Wang T, Li M, Liu F, Xiong L, Wang K, He T, Shi J, Song Y, Zhao Y, Li N, Yu Z, Meng Q., Free PMC Article

    07/3/2021
    Interleukin-34 contributes to poor prognosis in triple-negative breast cancer.

    Interleukin-34 contributes to poor prognosis in triple-negative breast cancer.
    Kajihara N, Kitagawa F, Kobayashi T, Wada H, Otsuka R, Seino KI.

    06/26/2021
    Effects of IL-34 on Macrophage Immunological Profile in Response to Alzheimer's-Related Abeta42 Assemblies.

    Effects of IL-34 on Macrophage Immunological Profile in Response to Alzheimer's-Related Aβ(42) Assemblies.
    Zuroff LR, Torbati T, Hart NJ, Fuchs DT, Sheyn J, Rentsendorj A, Koronyo Y, Hayden EY, Teplow DB, Black KL, Koronyo-Hamaoui M., Free PMC Article

    04/24/2021
    Function of CSF1 and IL34 in Macrophage Homeostasis, Inflammation, and Cancer.

    Function of CSF1 and IL34 in Macrophage Homeostasis, Inflammation, and Cancer.
    Lin W, Xu D, Austin CD, Caplazi P, Senger K, Sun Y, Jeet S, Young J, Delarosa D, Suto E, Huang Z, Zhang J, Yan D, Corzo C, Barck K, Rajan S, Looney C, Gandham V, Lesch J, Liang WC, Mai E, Ngu H, Ratti N, Chen Y, Misner D, Lin T, Danilenko D, Katavolos P, Doudemont E, Uppal H, Eastham J, Mak J, de Almeida PE, Bao K, Hadadianpour A, Keir M, Carano RAD, Diehl L, Xu M, Wu Y, Weimer RM, DeVoss J, Lee WP, Balazs M, Walsh K, Alatsis KR, Martin F, Zarrin AA., Free PMC Article

    10/24/2020
    CSF1R Ligands IL-34 and CSF1 Are Differentially Required for Microglia Development and Maintenance in White and Gray Matter Brain Regions.

    CSF1R Ligands IL-34 and CSF1 Are Differentially Required for Microglia Development and Maintenance in White and Gray Matter Brain Regions.
    Easley-Neal C, Foreman O, Sharma N, Zarrin AA, Weimer RM., Free PMC Article

    10/24/2020
    This study describes for the first time the expression of IL-34 in multiple myeloma cells, indicating that it may enhance osteolysis. Targeting Il34 by specific small interfering RNA impaired osteoclast formation in vitro and attenuated osteolytic disease in vivo.

    A role for IL-34 in osteolytic disease of multiple myeloma.
    Baghdadi M, Ishikawa K, Nakanishi S, Murata T, Umeyama Y, Kobayashi T, Kameda Y, Endo H, Wada H, Bogen B, Yamamoto S, Yamaguchi K, Kasahara I, Iwasaki H, Takahata M, Ibata M, Takahashi S, Goto H, Teshima T, Seino KI., Free PMC Article

    03/7/2020
    found that the loss of interleukin-34 resulted in higher sensitivity to Con A-induced hepatitis

    Interleukin-34 drives macrophage polarization to the M2 phenotype in autoimmune hepatitis.
    Liu Y, Liu H, Zhu J, Bian Z.

    01/18/2020
    The IL-34 acts as a proinflammatory factor, aggravating the severity of arthritis in CIA mice by inducing the production of IL-17.

    Interleukin-34 Aggravates the Severity of Arthritis in Collagen-Induced Arthritis Mice by Inducing Interleukin-17 Production.
    Zhang L, Cui M, Ding L, Xia L, Lu J, Shen H.

    10/26/2019
    These results indicated a novel GRP78-dependent localization and specific function of IL-34 in FL-Y cells related to monocytic cell differentiation.

    Interleukin 34 (IL-34) cell-surface localization regulated by the molecular chaperone 78-kDa glucose-regulated protein facilitates the differentiation of monocytic cells.
    Ogawa S, Matsuoka Y, Takada M, Matsui K, Yamane F, Kubota E, Yasuhara S, Hieda K, Kanayama N, Hatano N, Tokumitsu H, Magari M., Free PMC Article

    05/4/2019
    The current study aimed to assess the IL-34 expression in response to two members of the transforming growth factor (TGF)-beta family, TGF-beta1 and bone morphogenetic protein (BMP)-2, in synovial fibroblasts from rheumatoid arthritis patients.

    Bone Morphogenetic Protein 2 and Transforming Growth Factor β1 Inhibit the Expression of the Proinflammatory Cytokine IL-34 in Rheumatoid Arthritis Synovial Fibroblasts.
    Chemel M, Brion R, Segaliny AI, Lamora A, Charrier C, Brulin B, Maugars Y, Le Goff B, Heymann D, Verrecchia F.

    05/27/2017
    study concludes that Langerhans cells require IL-34 when residing in fully differentiated and anatomically intact skin epidermis, but rely on neutrophil-derived CSF1 during inflammation

    Nonredundant roles of keratinocyte-derived IL-34 and neutrophil-derived CSF1 in Langerhans cell renewal in the steady state and during inflammation.
    Wang Y, Bugatti M, Ulland TK, Vermi W, Gilfillan S, Colonna M., Free PMC Article

    08/6/2016
    constitutive IL-34 expressed by skin keratinocytes might suppress resident macrophage responses to C. albicans colonisation by maintaining low levels TLR2 and Dectin-1 expression by macrophages.

    IL-34 Suppresses Candida albicans Induced TNFα Production in M1 Macrophages by Downregulating Expression of Dectin-1 and TLR2.
    Xu R, Sun HF, Williams DW, Jones AV, Al-Hussaini A, Song B, Wei XQ., Free PMC Article

    03/26/2016
    IL-34 protected blood-brain barrier integrity by restored expression levels of tight junction proteins, which were downregulated by pro-inflammatory cytokines.

    Interleukin-34 restores blood-brain barrier integrity by upregulating tight junction proteins in endothelial cells.
    Jin S, Sonobe Y, Kawanokuchi J, Horiuchi H, Cheng Y, Wang Y, Mizuno T, Takeuchi H, Suzumura A., Free PMC Article

    12/5/2015
    IL-34-dependent, Mo-mediated, CSF-1 nonredundant mechanisms promote persistent ischemia-incited AKI that worsens subsequent CKD.

    IL-34 mediates acute kidney injury and worsens subsequent chronic kidney disease.
    Baek JH, Zeng R, Weinmann-Menke J, Valerius MT, Wada Y, Ajay AK, Colonna M, Kelley VR., Free PMC Article

    10/24/2015
    In vitro and in vivo experiments indicate that IL-34 expression is regulated by TNF-a and IL-1b and that its overexpression is associated with an increase in osteosarcoma growth and metastasis.

    Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment.
    Ségaliny AI, Mohamadi A, Dizier B, Lokajczyk A, Brion R, Lanel R, Amiaud J, Charrier C, Boisson-Vidal C, Heymann D.

    07/25/2015
    firstprevious page of 2 nextlast